Top 47 medical and healthcare startups in China
Jan 21, 2026
|
Like
29
1
Funding: $370M
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
2
Funding: $100M
OTR Therapeutics is a biotechnology company developing platform-based treatments using modular RNA and delivery systems. Its pipeline covers differentiated programs that target significant treatment gaps in immunology and inflammation, oncology and neurologу. The company is a member of Bayer’s Co.Lab life sciences incubator network.
OTR Therapeutics is a biotechnology company developing platform-based treatments using modular RNA and delivery systems. Its pipeline covers differentiated programs that target significant treatment gaps in immunology and inflammation, oncology and neurologу. The company is a member of Bayer’s Co.Lab life sciences incubator network.
3
Funding: $1.5B
WeDoctor Group is an online healthcare service provider through its mobile apps and Guahao online portal
WeDoctor Group is an online healthcare service provider through its mobile apps and Guahao online portal
4
Funding: $1.4B
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics.
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics.
5
Funding: $920.3M
MediTrust Health is a leading medical innovation payment service brand in China.
MediTrust Health is a leading medical innovation payment service brand in China.
6
Funding: $737.6M
Rakuten Aspyrian is developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy.
Rakuten Aspyrian is developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy.
7
Funding: $682M
DXY is an online healthcare community for doctors, consumers, and healthcare organizations.
DXY is an online healthcare community for doctors, consumers, and healthcare organizations.
8
Funding: $631.7M
Waterdrop is an online insurance technology platform that plans to solve the problem of high medical fees faced by many patients.
Waterdrop is an online insurance technology platform that plans to solve the problem of high medical fees faced by many patients.
9
Funding: $504.7M
Ascentage Pharma is a China-based, global-oriented company focused on the discovery and development of targeted small molecule anti-cancer therapies. The company leverages own breakthrough chemistry to synthesize inhibitors that target proteins (Bcl-2, Bcl-2/Bcl-xL, IAP, and MDM2) and signaling pathways that define key cancer hallmarks (e.g., BCR-ABL1, ALK, and FAK inhibitors). It also develops therapies such as PROTACs (Protein Acid Carcinogenesis Acids) that target traditionally untreatable proteins involved in oncogenesis. The company is conducting clinical trials of drugs against chronic lymphocytic leukemia, acute myeloid leukemia, small lymphocytic lymphoma, adrenocortical carcinoma, malignant peripheral nerve sheath tumor, and non-small cell lung cancer.
Ascentage Pharma is a China-based, global-oriented company focused on the discovery and development of targeted small molecule anti-cancer therapies. The company leverages own breakthrough chemistry to synthesize inhibitors that target proteins (Bcl-2, Bcl-2/Bcl-xL, IAP, and MDM2) and signaling pathways that define key cancer hallmarks (e.g., BCR-ABL1, ALK, and FAK inhibitors). It also develops therapies such as PROTACs (Protein Acid Carcinogenesis Acids) that target traditionally untreatable proteins involved in oncogenesis. The company is conducting clinical trials of drugs against chronic lymphocytic leukemia, acute myeloid leukemia, small lymphocytic lymphoma, adrenocortical carcinoma, malignant peripheral nerve sheath tumor, and non-small cell lung cancer.
10
Funding: $343.7M
Clover Biopharmaceuticals is a clinical-stage biotechnology company focused on developing novel and transformative biologic therapies.
Clover Biopharmaceuticals is a clinical-stage biotechnology company focused on developing novel and transformative biologic therapies.
11
Funding: $312.8M
Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and inflammatory diseases.
Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and inflammatory diseases.
12
Funding: $288.8M
Tianjin CanSino Biotech is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.
Tianjin CanSino Biotech is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.
13
Funding: $276M
Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics.
Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics.
14
Funding: $272.9M
Chinese smartphone app that lets users remotely consult with physicians to diagnose their ailments
Chinese smartphone app that lets users remotely consult with physicians to diagnose their ailments
15
Funding: $220M
Dingdang Health’s online-to-offline model enables it to supply drugs from the pharma manufacturers and offline pharmacies to meet users’ urgent medical needs.
Dingdang Health’s online-to-offline model enables it to supply drugs from the pharma manufacturers and offline pharmacies to meet users’ urgent medical needs.
16
Funding: $214.7M
Beijing Infervision is an artificial intelligence high-tech company committed to applying deep learning technology to assist medical image diagnosis as efficient and accurate solutions. Infervision effectively uses various types of medical data to create clinically valued products and promotes precision analysis in the medical field especially in assisted image diagnosis.
Beijing Infervision is an artificial intelligence high-tech company committed to applying deep learning technology to assist medical image diagnosis as efficient and accurate solutions. Infervision effectively uses various types of medical data to create clinically valued products and promotes precision analysis in the medical field especially in assisted image diagnosis.
17
Funding: $200M
iCarbonX aims to build an ecosystem of digital life based on a combination of an individual’s biological, behavioral and psychological data, the Internet and artificial intelligence.
iCarbonX aims to build an ecosystem of digital life based on a combination of an individual’s biological, behavioral and psychological data, the Internet and artificial intelligence.
18
Funding: $195M
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.
19
Funding: $190M
JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
20
Funding: $180M
Adagene is an anticancer antibody discovery and engineering company which seeks to establish technology-driven discovery partnerships.
Adagene is an anticancer antibody discovery and engineering company which seeks to establish technology-driven discovery partnerships.
21
Funding: $179.7M
EdiGene is a biotechnology company that develops genome editing technologies.
EdiGene is a biotechnology company that develops genome editing technologies.
23
Funding: $151.2M
Ehang is a technology enterprise focused on R&D and production in airplane and aircraft field.
Ehang is a technology enterprise focused on R&D and production in airplane and aircraft field.
25
Funding: $101.6M
Juventas develops and manufactures cellular immunotherapies for the treatment of cancer. The company has more than 10 drug candidates, including innovative single- and multi-targeted therapies and general cell therapy products. Its flagship candidate, Inaticabtagene Autoleucel, is the first CAR-T therapy targeting CD19 in China. It is undergoing clinical trials for the treatment of relapsed and refractory acute lymphoblastic leukemia in adults, relapsed and refractory aggressive B-cell non-Hodgkin's lymphoma, and B-cell acute lymphoblastic leukemia in children and adolescents. It has received Breakthrough Therapy designation from the Center for Drug Evaluation from China's NMPA and Orphan Drug designation from FDA.
Juventas develops and manufactures cellular immunotherapies for the treatment of cancer. The company has more than 10 drug candidates, including innovative single- and multi-targeted therapies and general cell therapy products. Its flagship candidate, Inaticabtagene Autoleucel, is the first CAR-T therapy targeting CD19 in China. It is undergoing clinical trials for the treatment of relapsed and refractory acute lymphoblastic leukemia in adults, relapsed and refractory aggressive B-cell non-Hodgkin's lymphoma, and B-cell acute lymphoblastic leukemia in children and adolescents. It has received Breakthrough Therapy designation from the Center for Drug Evaluation from China's NMPA and Orphan Drug designation from FDA.
26
Funding: $96.3M
Sinovac Biotech is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) ...
Sinovac Biotech is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) ...
28
Funding: CN¥576M
Chenglian Technology is a high-tech enterprise that focuses on the digital manufacturing of the whole process of dentistry.
Chenglian Technology is a high-tech enterprise that focuses on the digital manufacturing of the whole process of dentistry.
29
Funding: $78.5M
VoxelCloud provides automated medical image analysis services and diagnosis assistance based on AI and cloud computing technologies. VoxelCloud develops computer-aided detection systems for detecting and diagnosing various diseases ranging from cardiovascular and lung diseases to eye diseases. Our solutions are based on the state-of-the-art computer vision, deep learning and artificial intelligence technology.
VoxelCloud provides automated medical image analysis services and diagnosis assistance based on AI and cloud computing technologies. VoxelCloud develops computer-aided detection systems for detecting and diagnosing various diseases ranging from cardiovascular and lung diseases to eye diseases. Our solutions are based on the state-of-the-art computer vision, deep learning and artificial intelligence technology.
30
Funding: $65.5M
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure.
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure.
31
Funding: CN¥400M
Qihe Biotech develops novel genome editing technologies with an emphasis on making them autonomous and programmable.
Qihe Biotech develops novel genome editing technologies with an emphasis on making them autonomous and programmable.
33
Funding: $49.4M
MORE Health's multi-lingual co-diagnosis system includes information such as an assessment of the patient’s condition, treatment plan, doctor notes, data from physical exams, lab result documents and images. It also provides an area for doctors to be added to the team treating the patient and another section shows the discussion thread between physicians.
MORE Health's multi-lingual co-diagnosis system includes information such as an assessment of the patient’s condition, treatment plan, doctor notes, data from physical exams, lab result documents and images. It also provides an area for doctors to be added to the team treating the patient and another section shows the discussion thread between physicians.
34
Funding: $45.2M
Immunochina provides cancer diagnosis and treatment services based on Chimeric Antigen Receptor T-cell immunotherapy.
Immunochina provides cancer diagnosis and treatment services based on Chimeric Antigen Receptor T-cell immunotherapy.
35
Funding: CN¥201M
12 Sigma is an innovative healthcare company with leading artificial intelligence technology and medical imaging applications.
12 Sigma is an innovative healthcare company with leading artificial intelligence technology and medical imaging applications.
36
Funding: $30M
Huimei Technology develops and designs medical artificial intelligence solutions that focus on improving clinical quality. Products include clinical decision support system, disease process quality management system, medical knowledge base, using natural language processing, deep learning and other AI techniques to process clinical big data.
Huimei Technology develops and designs medical artificial intelligence solutions that focus on improving clinical quality. Products include clinical decision support system, disease process quality management system, medical knowledge base, using natural language processing, deep learning and other AI techniques to process clinical big data.
37
Funding: CN¥133.7M
MedPrin is a high-tech enterprise co-founded by outstanding biomedicine scientists in September 2008, specialized in R & D, production and sales of regenerative medicine materials and regenerative implantable medical devices. MEDPRIN aims to become global leader in the field of implantable medical devices, relying on amazing capacity to provide excellent products for the patients worldwide based on biological 3D printing technology and nano-bionics technology
MedPrin is a high-tech enterprise co-founded by outstanding biomedicine scientists in September 2008, specialized in R & D, production and sales of regenerative medicine materials and regenerative implantable medical devices. MEDPRIN aims to become global leader in the field of implantable medical devices, relying on amazing capacity to provide excellent products for the patients worldwide based on biological 3D printing technology and nano-bionics technology
38
Funding: $23.1M
The CareVoice is a health InsurTech company that provides a mobile-based data-driven SaaS platform.
The CareVoice is a health InsurTech company that provides a mobile-based data-driven SaaS platform.
39
Funding: $23.1M
Mobile social platform bringing better healthcare experience to its communities, especially insurance members and employees. Provides AI voice-based virtual health assistant for insurers and employers
Mobile social platform bringing better healthcare experience to its communities, especially insurance members and employees. Provides AI voice-based virtual health assistant for insurers and employers
40
Funding: $20M
Developer of cancer therapies based on disease models intended to treat stomach and breast cancer. The company leverages disease models and artificial intelligence technology to develop cancer treatment.
Developer of cancer therapies based on disease models intended to treat stomach and breast cancer. The company leverages disease models and artificial intelligence technology to develop cancer treatment.
41
Funding: $15M
META Pharmaceuticals is a cutting-edge drug development company specializing in autoimmune diseases.
META Pharmaceuticals is a cutting-edge drug development company specializing in autoimmune diseases.
42
Funding: $15M
Siyi Intelligence specializes in the design, development and commercialization of cutting-edge solutions in rehabilitation, in particular medical rehabilitation robots.
Siyi Intelligence specializes in the design, development and commercialization of cutting-edge solutions in rehabilitation, in particular medical rehabilitation robots.
43
Funding: $13.5M
Hekaiwei is a provider of innovative solutions for women's health.
Hekaiwei is a provider of innovative solutions for women's health.
45
Junshi Biosciences is an innovation-driven biopharmaceutical company which is dedicated to the discovery and development of innovative drugs and their clinical research and commercialization on a global scale.
46
Funding: CN¥33M
Chinese company, founded in 2013. Commercializing bioprinter “Regenovo” for “making biomaterials, organs and tissues” for regenerative medicine.
Chinese company, founded in 2013. Commercializing bioprinter “Regenovo” for “making biomaterials, organs and tissues” for regenerative medicine.
47
Funding: $2.7M
Deep01 is a Taiwanese startup that develops software to help doctors interpret CT brain scans more quickly
Deep01 is a Taiwanese startup that develops software to help doctors interpret CT brain scans more quickly
★
See also:
